“We are really happy that we could attract an experienced and successful executive like Brian Hutchison to Raumedic,” Stefan Seuferling said. “The U.S. market is filled with potential for Raumedic. We really believe that we will be able to continue expanding our business activities there now that we have brought Brian Hutchison on board.”
Brian Hutchison is an experienced executive in the international medical technology market. The U.S. native has more than 30 years of experience in the areas of medical devices and biotechnology. He was the ideal candidate for the position, thanks in part to his vast understanding of medical technology and the pharmaceutical industry and the valuable management experience he has gained in high-ranking positions at Stryker Corporation, RTI Surgical and Catalyst OrthoScience.
As the new President and CEO of Raumedic Inc., Brian Hutchison said he would “provide crucial momentum that would produce far-reaching strategies and long-term growth for Raumedic together with our customers, partners and employees.” He said he planned to focus in particular on expanding the Business Units, an effort that will focus explicitly on the pharmaceutical market in addition to medical technology. “Pharma fluid handling, cell therapy and drug delivery are just three areas where I see tremendous growth potential,” Hutchison said.
The Raumedic Group places people’s health at the center of its business activities. The company processes medical-grade thermoplastic polymers and silicones at its five production plants in Germany and the United States. Raumedic is a company with more 70 years for experience in extrusion, injection molding and assembly and about 1,000 employees worldwide. It turns customer ideas into real products.
Working as a partner of the international medical-technology and pharmaceutical industry, the polymer specialist develops and produces customer-specific components like tubing, catheters and molded parts as well as complex component groups and systems used to make diagnoses and provide therapy. Raumedic makes highly precise pressure-measuring systems with microchip technology for the specialized clinical fields neuromonitoring and traumatology. The Raumedic Group generates average sales growth of 8 percent annually. Total sales reached €138.7 million in 2020.